Generali Investments Towarzystwo Funduszy Inwestycyjnych Increases Position in CRISPR Therapeutics AG (NASDAQ:CRSP)

Generali Investments Towarzystwo Funduszy Inwestycyjnych boosted its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 26.7% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 19,000 shares of the company’s stock after purchasing an additional 4,000 shares during the period. Generali Investments Towarzystwo Funduszy Inwestycyjnych’s holdings in CRISPR Therapeutics were worth $748,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Whipplewood Advisors LLC bought a new stake in shares of CRISPR Therapeutics in the fourth quarter valued at $159,000. ARK Investment Management LLC raised its stake in CRISPR Therapeutics by 19.7% in the 4th quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company’s stock valued at $353,180,000 after acquiring an additional 1,474,439 shares during the period. Bank of New York Mellon Corp lifted its holdings in CRISPR Therapeutics by 2.1% during the fourth quarter. Bank of New York Mellon Corp now owns 76,569 shares of the company’s stock valued at $3,014,000 after purchasing an additional 1,553 shares during the last quarter. First Horizon Advisors Inc. boosted its position in CRISPR Therapeutics by 33.4% during the fourth quarter. First Horizon Advisors Inc. now owns 2,039 shares of the company’s stock worth $80,000 after purchasing an additional 511 shares during the period. Finally, Ipswich Investment Management Co. Inc. increased its stake in shares of CRISPR Therapeutics by 3.1% in the fourth quarter. Ipswich Investment Management Co. Inc. now owns 25,288 shares of the company’s stock worth $995,000 after purchasing an additional 750 shares in the last quarter. Hedge funds and other institutional investors own 69.20% of the company’s stock.

Insider Activity

In other news, CEO Samarth Kulkarni sold 15,000 shares of the company’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $55.10, for a total value of $826,500.00. Following the completion of the sale, the chief executive officer now owns 181,540 shares of the company’s stock, valued at approximately $10,002,854. This represents a 7.63 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 4.10% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the stock. Royal Bank of Canada dropped their price target on shares of CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating on the stock in a research note on Wednesday, February 12th. Needham & Company LLC reiterated a “buy” rating and set a $84.00 price objective on shares of CRISPR Therapeutics in a research note on Wednesday, February 12th. Cantor Fitzgerald restated a “neutral” rating on shares of CRISPR Therapeutics in a research note on Wednesday, February 19th. Stifel Nicolaus cut their target price on CRISPR Therapeutics from $53.00 to $49.00 and set a “hold” rating for the company in a research note on Thursday, February 13th. Finally, The Goldman Sachs Group cut their target price on CRISPR Therapeutics from $66.00 to $57.00 and set a “neutral” rating for the company in a research note on Thursday, February 13th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, CRISPR Therapeutics has a consensus rating of “Hold” and a consensus target price of $74.40.

CRISPR Therapeutics Price Performance

Shares of NASDAQ:CRSP opened at $43.62 on Friday. The company’s fifty day moving average price is $42.36 and its 200-day moving average price is $45.99. The firm has a market capitalization of $3.74 billion, a price-to-earnings ratio of -9.98 and a beta of 1.67. CRISPR Therapeutics AG has a one year low of $36.52 and a one year high of $90.62.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. As a group, equities research analysts expect that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.